TheLiRep
Financiado
Exploring the Potential for Therapeutic Lineage Reprogramming of Diabetes
Diabetes is a degenerative disease that affects over 350 million persons worldwide. Type 1 and type 2 diabetes are associated with either destruction or dysfunction of pancreatic insulin-producing β cells. Despite the availability...
Diabetes is a degenerative disease that affects over 350 million persons worldwide. Type 1 and type 2 diabetes are associated with either destruction or dysfunction of pancreatic insulin-producing β cells. Despite the availability of insulin as treatment to temporarily restore the glucostasis, this remedy is unable to avoid either the acute dangers of hypoglycemia or the long-term complications of hyperglycemia. Eventually, the challenge of treating diabetes centers on the replacement of pancreatic β cells. Due to serious organ shortage for pancreas transplantation, cell-based therapy represents the most promising option and different potential sources for new β cells are currently being explored, including embryonic stem cells and other cell types. A particularly attractive therapeutic strategy is to convert liver adult cells of diabetic patients into functional pancreatic β cells through lineage reprogramming. Fate conversion of liver to pancreas is conceivable for numerous physiological and developmental reasons, and, possibly, suitable for future clinical applications. My ERC-funded project (ERC Starting Grant HEPATOPANCREATIC) is focused on the molecular mechanisms underlying cellular plasticity between liver and pancreatic cells. This study has led to the identification of a novel factor, whose ectopic expression converts mouse liver cells into pancreatic cells. Here, we propose a defined and focused set of measures aimed at: 1) extending these findings in human liver cells to assess whether this strategy may be exploited to develop an autologous cell-based therapy of diabetes; and 2) elaborating a solid intellectual property strategy. The TheLiRep Proof of Concept (PoC) funding will ensure the full exploitation of the ERC idea and bridge the gap between my research and the earliest stage of a marketable innovation.
ver más
Duración del proyecto: 19 meses
Fecha Inicio: 2015-03-11
Fecha Fin: 2016-10-31
Fecha Fin: 2016-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2016-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-PoC-2014:
ERC Proof of Concept Grant
Cerrada
hace 10 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN...
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
1.14M€ |
Participante